Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity

Journal:

Nature Communications

Published:

2025-09-24

DOI:

10.1038/s41467-025-61817-8

Affiliations:

13

Authors:

26

Go to article

Institutions	Authors	Share
The University of Texas MD Anderson Cancer Center, United States of America (USA)	13.000000 13.000000	0.50
Takeda Cambridge Ltd., United Kingdom (UK)	3.000000	0.12
NASA Ames Research Center (ARC), United States of America (USA)	2.000000	0.08
Spectrum Pharmaceuticals, Inc., United States of America (USA)	2.000000	0.08
KBR, United States of America (USA)	1.000000	0.04
The University of Chicago (UChicago), United States of America (USA)	1.000000	0.04
Duke University Hospital, United States of America (USA)	1.000000	0.04
City of Hope, United States of America (USA)	1.000000	0.04
UCLA Health, United States of America (USA)	1.000000	0.04
AdventHealth, United States of America (USA)	1.000000	0.04

Interested in Oncology and Carcinogenesis?